
Monoclonal Antibodies Market by Source Type (Chimeric, Human, Humanized), Production Type (In Vitro, In Vivo), Indication, End-User - Global Forecast 2024-2030
Description
Monoclonal Antibodies Market by Source Type (Chimeric, Human, Humanized), Production Type (In Vitro, In Vivo), Indication, End-User - Global Forecast 2024-2030
The Monoclonal Antibodies Market size was estimated at USD 126.26 billion in 2023 and expected to reach USD 141.81 billion in 2024, at a CAGR 12.41% to reach USD 286.43 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Monoclonal Antibodies Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Monoclonal Antibodies Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Monoclonal Antibodies Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie, Inc., ADC Therapeutics SA, Almac Group Limited, Amgen Inc., Astellas Pharma Inc., Biogen Inc., Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Novartis AG, Pfizer Inc., Sanofi S.A., and Thermo Fisher Scientific Inc..
Market Segmentation & Coverage
This research report categorizes the Monoclonal Antibodies Market to forecast the revenues and analyze trends in each of the following sub-markets:
Source Type
Chimeric
Human
Humanized
Murine
Production Type
In Vitro
In Vivo
Indication
Autoimmune Diseases
Cancer
Infectious Diseases
Inflammatory Diseases
Microbial Diseases
End-User
Hospitals
Research Institutes
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Monoclonal Antibodies Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Monoclonal Antibodies Market?
3. What are the technology trends and regulatory frameworks in the Monoclonal Antibodies Market?
4. What is the market share of the leading vendors in the Monoclonal Antibodies Market?
5. Which modes and strategic moves are suitable for entering the Monoclonal Antibodies Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
184 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Monoclonal Antibodies Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Increasing prevalence of cost-efficient biosimilar monoclonal antibodies
- 5.1.1.2. Rising incidence of cancer and other chronic diseases
- 5.1.1.3. Increasing R&D activities in genomics coupled with the advent of technologically advanced genetic platforms
- 5.1.2. Restraints
- 5.1.2.1. Pricing of therapeutic mAbs are high
- 5.1.3. Opportunities
- 5.1.3.1. Substantial increase in the number of approvals per year
- 5.1.3.2. Improvements in supply chain and distribution network
- 5.1.4. Challenges
- 5.1.4.1. Limitation in current manufacturing and purification processes
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Monoclonal Antibodies Market, by Source Type
- 6.1. Introduction
- 6.2. Chimeric
- 6.3. Human
- 6.4. Humanized
- 6.5. Murine
- 7. Monoclonal Antibodies Market, by Production Type
- 7.1. Introduction
- 7.2. In Vitro
- 7.3. In Vivo
- 8. Monoclonal Antibodies Market, by Indication
- 8.1. Introduction
- 8.2. Autoimmune Diseases
- 8.3. Cancer
- 8.4. Infectious Diseases
- 8.5. Inflammatory Diseases
- 8.6. Microbial Diseases
- 9. Monoclonal Antibodies Market, by End-User
- 9.1. Introduction
- 9.2. Hospitals
- 9.3. Research Institutes
- 10. Americas Monoclonal Antibodies Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
- 11. Asia-Pacific Monoclonal Antibodies Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
- 12. Europe, Middle East & Africa Monoclonal Antibodies Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
- 13. Competitive Landscape
- 13.1. FPNV Positioning Matrix
- 13.2. Market Share Analysis, By Key Player
- 13.3. Competitive Scenario Analysis, By Key Player
- 14. Competitive Portfolio
- 14.1. Key Company Profiles
- 14.1.1. Abbott Laboratories
- 14.1.2. AbbVie, Inc.
- 14.1.3. ADC Therapeutics SA
- 14.1.4. Almac Group Limited
- 14.1.5. Amgen Inc.
- 14.1.6. Astellas Pharma Inc.
- 14.1.7. Biogen Inc.
- 14.1.8. Bristol Myers Squibb Company
- 14.1.9. Eli Lilly and Company
- 14.1.10. F. Hoffmann-La Roche Ltd.
- 14.1.11. Johnson & Johnson Services, Inc.
- 14.1.12. Novartis AG
- 14.1.13. Pfizer Inc.
- 14.1.14. Sanofi S.A.
- 14.1.15. Thermo Fisher Scientific Inc.
- 14.2. Key Product Portfolio
- 15. Appendix
- 15.1. Discussion Guide
- 15.2. License & Pricing
- FIGURE 1. MONOCLONAL ANTIBODIES MARKET RESEARCH PROCESS
- FIGURE 2. MONOCLONAL ANTIBODIES MARKET SIZE, 2023 VS 2030
- FIGURE 3. MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. MONOCLONAL ANTIBODIES MARKET DYNAMICS
- FIGURE 7. MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2023 VS 2030 (%)
- FIGURE 8. MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2023 VS 2030 (%)
- FIGURE 10. MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
- FIGURE 12. MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
- FIGURE 14. MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 16. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 18. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 23. MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 24. MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.